Expert opinion on optimising type 2 diabetes treatment using fixed-ratio combination of basal insulin and GLP-1 RA for treatment intensification and simplification
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084935" target="_blank" >RIV/00023001:_____/24:00084935 - isvavai.cz</a>
Result on the web
<a href="https://link.springer.com/article/10.1007/s13300-024-01610-w" target="_blank" >https://link.springer.com/article/10.1007/s13300-024-01610-w</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s13300-024-01610-w" target="_blank" >10.1007/s13300-024-01610-w</a>
Alternative languages
Result language
angličtina
Original language name
Expert opinion on optimising type 2 diabetes treatment using fixed-ratio combination of basal insulin and GLP-1 RA for treatment intensification and simplification
Original language description
The management of type 2 diabetes (T2D) often necessitates treatment intensification, and sometimes simplification to achieve glycaemic targets and mitigate complications. This expert opinion paper evaluates the use and positioning of the fixed-ratio combinations (FRCs) of basal insulin (BI) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in optimising T2D management. On the basis of the evidence presented and discussions, these FRCs offer a promising approach for both treatment intensification and simplification in people with suboptimal glucose control despite receiving various therapies. In treatment intensification, FRCs provide a synergistic effect by addressing multiple pathophysiological defects contributing to hyperglycaemia. These FRCs effectively control both fasting and postprandial glucose (PPG) excursions, offering significantly improved glycaemic control with a lower hypoglycaemia risk and weight neutrality compared to traditional or complex insulin regimens. Moreover, the reduced injection frequency (once daily) and flexibility in the dosing schedule (with any major meal of the day) help mitigate patient resistance to insulin initiation or titration. This further reduces treatment burden, facilitating treatment adherence and enhancing patient convenience. These key benefits of FRCs over complex insulin regimens play a crucial role in long-term glycaemic management and overall treatment outcomes. Hence, the timely use of FRCs in the treatment algorithm for people with T2D represents a valuable strategy for optimising glycaemic control, addressing treatment barriers and enhancing patient-reported outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes therapy
ISSN
1869-6953
e-ISSN
1869-6961
Volume of the periodical
15
Issue of the periodical within the volume
8
Country of publishing house
DE - GERMANY
Number of pages
13
Pages from-to
1673-1685
UT code for WoS article
001256959700002
EID of the result in the Scopus database
2-s2.0-85197871440